Top-News
Dienstag,
30.07.2019 17:31
von
PR Newswire
| Aufrufe: 189
Lemelson Capital Increases Short Position in Ligand Pharmaceuticals (NASDAQ: LGND), Calls on US Attorney to Investigate
Verschiedene Medikamente in Tabletten- und Kapselform. (Symbolbild)
© pixabay.com/CC0
https://pixabay.com
PR Newswire
SHELBURNE, Vt., July 30, 2019
SHELBURNE, Vt., July 30, 2019 /PRNewswire/ -- Lemelson Capital Management (LCM), a private investment management firm, today announced that it had increased its short position in Ligand Pharmaceuticals (NASDAQ: LGND). The firm today also called on the US Attorney's office for the Southern District of California to investigate Ligand for alleged criminal violations of federal securities laws amidst what LCM has called SEC failures.
LCM's 2014-2018 research and commentary charted the alleged fraud. As of today, Ligand's shares continue to plummet,1 contributing to a drop in the share price of as much as 65 percent since late September 2018, and destroying billions of dollars in shareholder value, even as markets recently achieved record highs.
To read Lemelson's prior research reports and commentary on Ligand click here
"Sadly, investors have been ruined by Ligand's alleged scheme while the SEC has ignored the red flags and botched opportunities for a proper investigation of the company," said Lemelson Capital's Chief Investment Officer Fr. Emmanuel Lemelson.
Disclosure: LCM is currently short shares of LGND for its clients and has been charged by the SEC in connection with its prior commentary on Ligand. LCM has denied all charges and is actively defending the matter.
About Lemelson Capital Management
Lemelson Capital Management, LLC is a private investment management firm focused on deep value and special situation investments. For more information, visit: http://www.lemelsoncapital.com or follow on Twitter @LemelsonCapital
About Rev. Fr. Emmanuel Lemelson:
Rev. Fr. Emmanuel Lemelson is the Chief Investment Officer of Lemelson Capital Management, LLC, follow his work at www.amvona.com or on Twitter @Lemelson
For further information, please contact:
Lemelson Capital Management, LLC
Investor and Media Relations
Telephone: 802-332-3833
1 Shares fell about 12 percent today following the company's earnings release.
View original content:http://www.prnewswire.com/news-releases/lemelson-capital-increases-short-position-in-ligand-pharmaceuticals-nasdaq-lgnd-calls-on-us-attorney-to-investigate-300893239.html
SOURCE Lemelson Capital Management, LLC
Werbung
Mehr Nachrichten zur Ligand Pharmaceuticals Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
